Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.5K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

619
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
619
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

781
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
781
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

934
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
934
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

567
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of kidney function on the metabolome in the general population.

PloS one·2026
Same author

When the proteome meets the metabolome observational and Mendelian randomization analyses.

Metabolism: clinical and experimental·2026
Same author

End Point-Based Threshold for the Ambulatory Arterial Stiffness Index.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

The proteomic profile of leisure time physical activity across two decades: implications for future cardiovascular risk and mortality.

European journal of preventive cardiology·2026
Same author

Plasma Protein Profile Associated With a Family History of Early-Onset Coronary Heart Disease.

Circulation. Genomic and precision medicine·2025
Same author

A multi-omics approach uncovers causality of IL6R on endotypes of subclinical carotid atherosclerosis and the possible role of the IL6R/OSMR pathway.

Cardiovascular research·2025

Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
05:30

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

1.3K

Plasma protein profiles in different heart failure phenotypes.

Lars Lind1, Mario Delgado-Velandia1

  • 1Department of Medical Sciences, Molecular Epidemiology, Uppsala University, Dag Hammarskjölds väg 14B, Uppsala 75185, Sweden.

ESC Heart Failure
|April 12, 2026
PubMed
Summary

Researchers identified a shared plasma protein profile associated with heart failure (HF), regardless of prior myocardial infarction (MI) or atrial fibrillation (AF). This profile reveals key pathophysiological pathways linked to HF development.

Keywords:
Atrial fibrillationHeart failureMyocardial infarctionProteomicsSwedenUK Biobank

More Related Videos

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.5K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

789

Related Experiment Videos

Last Updated: Apr 14, 2026

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
05:30

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

1.3K
Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.5K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

789

Area of Science:

  • Cardiovascular Disease Research
  • Proteomics and Biomarker Discovery
  • Genomics and Bioinformatics

Background:

  • Heart failure (HF) often follows other cardiac conditions like myocardial infarction (MI) and atrial fibrillation (AF).
  • Understanding the underlying plasma protein profiles in HF development is crucial for early detection and targeted therapies.
  • Investigating distinct HF subtypes based on preceding conditions may reveal unique or shared molecular mechanisms.

Purpose of the Study:

  • To compare plasma protein profiles across three incident heart failure (HF) groups: HF with prior MI, HF with prior AF, and HF without prior MI or AF.
  • To identify a common set of plasma proteins associated with HF across all three groups.
  • To explore the relationship between identified protein profiles and cardiac function markers like left ventricular ejection fraction (LV-EF) and E/A ratio.

Main Methods:

  • Analysis of plasma protein data from 50,765 UK Biobank participants.
  • Categorization of incident HF cases into MI-HF, AF-HF, and noMInoAF-HF groups based on preceding conditions.
  • Utilized multivariable-adjusted Cox models to estimate hazard ratios for protein-HF associations and evaluated protein relationships with LV-EF and E/A ratio in subgroups.

Main Results:

  • Identified 110, 21, and 1 protein uniquely associated with HF in noMInoAF-HF, AF-HF, and MI-HF groups, respectively.
  • Discovered a shared profile of 60 proteins significantly associated with HF across all three groups.
  • Found 13 shared proteins related to LV-EF and 7 to E/A ratio, with LRRN1 inversely associated and ADM highly associated with HF in specific groups.

Conclusions:

  • A distinct plasma protein profile associated with heart failure was identified, independent of prior MI or AF.
  • This profile implicates several pathophysiological pathways and includes proteins linked to cardiac function parameters (LV-EF, E/A ratio).
  • Unique protein associations were also observed for specific HF subtypes, suggesting distinct underlying mechanisms.